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Abstract
Background: Human tyrosine-protein phosphatase non-receptor type substrate 1α (SIRPA) is a surface marker
identified in cardiomyocytes differentiated from human embryonic stem cells. Our objective was to determine if
circulating SIRPA levels can serve as a biomarker of cardiac injury in children undergoing open heart surgery.
Results: Paired pre- and post-operative serum samples from 48 pediatric patients undergoing open heart surgery
and from 6 pediatric patients undergoing non-cardiac surgery (controls) were tested for SIRPA protein levels using
commercially available SIRPA ELISA kits from two manufacturers. Post-operative SIRPA concentrations were significantly
higher in patients after cardiac surgery compared to non-cardiac surgery when tested using SIRPA ELISA kits from both
manufacturers. To verify the identity of the protein detected, recombinant human SIRPA protein (rhSIRPA) was tested
on both ELISA kits. The calibrator from both ELISA kits was analyzed by Western blot as well as by Mass Spectrometry
(MS). Western blot analysis of calibrators from both kits did not identity SIRPA. MS analysis of calibrators from both
ELISA kits identified several inflammatory markers and albumin but no SIRPA was detected.
Conclusions: We conclude that commercially available ELISA kits for SIRPA give false-positive results. Verifying protein
identity using robust protein characterization is critical to avoid false biomarker discovery when using commercial
ELISA kits.
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Background
The need for a robust cardiac biomarker for diagnosis,
risk stratification and tailored management of patients
with heart disease has resulted in considerable invest-
ment by both academic and industry researchers in the
search for a novel predictive biomarker that is sensitive,
specific and accurate. Although numerous cardiac bio-
markers have been identified in recent years and immu-
noassays have been developed, only a handful have been
successfully validated for clinical application due to fail-
ure along the various stages of the biomarker discovery
pipeline and/or their limited clinical impact on disease
prediction and risk stratification [1, 2].
Cardiac troponin is widely used as a sensitive bio-
marker of cardiac injury. However, it is not specific to
mechanism of injury, nor predictive of outcomes and is
often disproportionately elevated in renal insufficiency
[3]. SIRPA (Signal-regulatory protein alpha or Human
tyrosine-protein phosphatase non-receptor type substrate
1 or SHPS or CD172a) is a ~90 kDa transmembrane pro-
tein abundantly expressed in neurons, macrophages and
dendritic cells [4]. Along with other SIRP (Signal Regula-
tory protein) family members, SIRPβ and SIRPγ, SIRPA is
located on human chromosome 20p13 [5, 6]. SIRPA is in-
volved in various biological processes, including negative
regulation of immune cells and suppression of anchorage-
independent proliferative signal [7, 8]. SIRPA was first
identified as a cardiomyocyte-specific surface marker
using high-throughput flow cytometry screening of car-
diovascular cell lineages derived from human embryonic
stem cells (hESCs) against a panel of 370 known cluster of
differentiation antibodies [9]. A role for SIRPA in cardiac
diseases is not fully established except for one study show-
ing a protective role of SIRPA in cardiac hypertrophy
through negative regulation of the Toll-like receptor 4/nu-
clear factor-kB pathway in vitro [10]. Our objective was to
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determine if circulating serum SIRPA concentrations are
increased in children undergoing open heart surgery and
whether this represents a sensitive and specific marker of
cardiomyocyte injury. Our study revealed an increase in
post-operative circulating SIRPA concentrations measured
using commercial ELISA kits. Unfortunately, subsequent
protein validation studies failed to confirm the identity of
the detected protein as SIRPA highlighting a major




Children with heart disease undergoing cardiac and non-
cardiac surgery were recruited into the Heart Centre Bio-
bank Registry [11]. The study was approved by the
Research Ethics Board of the Hospital for Sick Children.
Written informed consent to participate and publish re-
sults was obtained from all parents/legal guardians/partic-
ipants. Serum samples were collected prior to cardiac
surgery and on post-operative days 1 and 2. Serum sam-
ples were stored at 4 °C for 24–48 h and then frozen at
-80 °C until analysis. Demographic data, diagnosis, surgery
type, and cardiopulmonary bypass duration were collected
from medical records. Patients were categorized by pres-
ence or absence of a left ventricular (LV) ventriculotomy
(incision in LV), or myectomy (resection of myocardium
from the LV). Patients undergoing non-cardiac surgery i.e.
liver or renal transplant were included as controls.
ELISA for SIRPA
All serum samples were analyzed for SIRPA concentration
using commercially available Sandwich-SIRPA ELISA kits
purchased from Cusabio Biotech Co, Ltd, Wuhan, China
(Catalog # CSB-EL021334HU) and Elabscience- Biotech
Co.Ltd, Wuhan, China (Catalog # E-EL-H1573). ELISA
assays on pre- and post-operative serum were performed
according to manufacturer’s instructions. After assay, Op-
tical Density (OD) was measured using Gemini EM mi-
croplate reader (Molecular Devices, USA) set at 450 nm
and change in SIRPA concentrations after surgery were
compared between the different surgical groups.
Western blot analysis of SIRPA ELISA kit calibrators
To verify the identity of the protein detected, Western
blot was performed on the calibrators from Cusabio and
Elabscience ELISA kits and compared to recombinant
human SIRPA (rhSIRPA) which was purchased from
Elabscience (Catalog # PN201773) to use as positive
control. Briefly, equal amount of protein from each
sample was separated by gel electrophoresis using Novex
10 % Tris-Glycine Gel (Life technologies, catalog no#
EC6078Box) following manufacturer’s instructions. Pro-
tein was transferred to PVDF membrane and blocked
with 5 % milk in TBST for 1 h. at room temperature
followed by overnight incubation with anti-human SIRPA
antibody (Biolegend, catalog # 323805) followed by 1 h in-
cubation with horseradish peroxidase-conjugated second-
ary antibody at room temperature.
Mass spectrometry analysis of ELISA kit calibrators
SIRPA ELISA kit calibrators from Cusabio and Elabscience
were also analyzed on an Orbitrap analyzer (Q-Exactive,
ThermoFisher, San Jose, CA) outfitted with a nanospray
source and EASY-nLC nano-LC system (ThermoFisher,
San Jose, CA) in order to determine if SIRPA was the tar-
get antigen for both calibrators. This was performed at the
SickKids SPARC Biocentre (Toronto, ON). The samples
were trypsin digested and lyophilized peptide mixtures
were dissolved in 0.1 % formic acid and loaded onto a
75 μm x 50 cm PepMax RSLC EASY-Spray column filled
with 2 μM C18 beads (ThermoFisher San, Jose CA) at a
pressure of 800 Bar. Peptides were eluted over 60 mins at
a rate of 250 nl/min using a 0 to 35 % acetonitrile gradient
in 0.1 % formic acid. Peptides were introduced by nano-
electrospray into the Q-Exactive mass spectrometer
(Thermo-Fisher). The instrument method consisted of
one MS full scan (400–1500 m/z) in the Orbitrap mass
analyzer with an automatic gain control (AGC) target of
1e6, maximum ion injection time of 120 ms and a reso-
lution of 70,000 followed by 10 data-dependent MS/MS
scans with a resolution of 17,500, an AGC target of 1e6,
maximum ion time of 120 ms, and one microscan. The in-
tensity threshold to trigger a MS/MS scan was set to 1.7e4.
Fragmentation occurred in the Higher –energy C-trap dis-
sociation with normalized collision energy set to 27. The
dynamic exclusion was applied using a setting of 5 s.
Statistical analysis
Serum SIRPA concentrations were expressed as mean ±
standard deviation. Samples were grouped by the type of
cardiac surgery i.e. no-ventriculotomy (n = 27), myect-
omy (n = 14), and ventriculotomy (n = 7). Samples from
non-cardiac surgery i.e. liver and renal transplant (n = 6)
were used as a controls. Statistical analysis was performed
by Student t-test to compare SIRPA concentrations in
cases and controls and to compare change in SIRPA con-
centrations in paired samples from pre- to post-operative
time-points. Differences were considered statistically sig-
nificant if p < 0.05. GraphPad PRISM 6.05 (GraphPad soft-
ware, USA) was used for statistical analysis.
Results
Elevated post-operative SIRPA concentrations using ELISA
Paired sera (n = 108), pre-operative and post-operative,
from 54 patients were used to measure serum SIRPA
concentration using Cusabio SIRPA ELISA kit. Post-
operative serum SIRPA concentrations were significantly
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higher in patients receiving ventriculotomy compared to
patients not receiving ventriculotomy (p < 0.0001), or
myectomy (p = 0.0004) and compared to those undergo-
ing non-cardiac surgery (p = 0.0001) (Fig. 1). To repli-
cate findings using another assay kit, we analyzed 4
serum samples (paired sera) from 2 patients using a
SIRPA ELISA assay kit from ElabScience, China. This
assay also detected a post-operative increase (0.184 ±
0.005 ng/ml and 5.104 ± 0.253 ng/ml) in serum SIRPA
concentrations compared to pre-operative concentra-
tions (0 ng/ml for both samples tested). To verify the
identity of the detected protein, we performed additional
experiments.
SIRPA ELISA kits failed to recognize pure rhSIRPA protein
We purchased full length, rhSIRPA protein from Elabscience
in order to verify that the protein being detected using
ELISA was SIRPA. rhSIRPA consists of 504 amino acids
and predicts a molecular mass of 55 kDa in its native form
and 60-65 kDA under reducing conditions due to glyco-
sylation. As a first step, we verified using MS that the
rhSIRPA from Elabscience was indeed SIRPA (see
Additional file 1: Table S1). After this verification, we ex-
amined the ability of the Cusabio and Elabscience ELISA
kits to detect known quantities of full length rhSIRPA
using serial known dilutions of rhSIRPA (0.156-10 ng/ml).
As shown in Fig. 2a and b, the OD 450 nm readings from
both assays were close to zero indicating that the assays
do not recognize full length rhSIRPA protein (Table 1)
even though both ELISA kits were able to recognize their
respective kit calibrators, producing linear calibration
curves (Fig. 2a and b).
Western blot analysis of SIRPA ELISA kit calibrators
We then performed Western blot analysis on the left-
over calibrators we could use from both ELISA kits
using anti-human SIRPA antibody from Biolegend (cata-
log # 323805) that has been previously used successfully
to detect SIRPA-positive cardiomyocytes [9]. As shown
in Fig. 2c, we detected a band of approximately 55 kDa
with rhSIRPA protein but not with either of the calibra-
tors suggesting that both calibrators do not react with
SIRPA antibody.
MS analysis of SIRPA ELISA kit calibrators
We then performed MS analysis of Cusabio and Elabscience
ELISA kit calibrators with rhSIRPA as a positive control.
rhSIRPA was readily detected using MS (Additional file 1:
Table S1). However, SIRPA was not detected in either
ELISA kit calibrator. Instead, the calibrators were found
to contain mostly albumin and a large number of other
proteins, including inflammatory proteins (Additional file 1:
Tables S2 and S3).
Discussion
In this report, we highlight the perils in biomarker dis-
covery when using protein assays that are poorly vali-
dated. We report a case of poorly characterized ELISA
kits purchased from two manufacturers that identify an-
tigens unrelated to the target analyte. Despite initial
findings of a post-operative increase in circulating SIRPA
protein in patients undergoing ventriculotomy on ELISA
testing from two manufacturers, extensive validation ex-
periments failed to replicate this finding. ELISA kits
from both manufacturers failed to recognize full length
rhSIRPA protein (MS verified, Table 1). MS analysis of
kit calibrators revealed that several inflammatory pro-
teins in addition to albumin were identified instead of
SIRPA (see Additional file 1: Tables S2 and S3). Even
after repeated request, we were unable to purchase/ob-
tain calibrators from the ELISA kit manufacturers for
further experiments.
Of note, Elabscience ELISA kit was unable to recognize
rhSIRPA protein manufactured by its own company
(Fig. 2b) which the company attributed to “spatial con-
formational change in rhSIRPA that may interfere with its
recognition by the ELISA kit”. Unfortunately, this high-
lights poor analytical validation of the product at the
source. To our knowledge, this is at least the third docu-
mented evidence of poorly validated commercial ELISA
kits that do not recognize the intended antigen. A similar
situation was encountered by Prassas et al. [12], where
they showed that a commercial ELISA kit purchased from
USCN life science (Wuhan, China) that was marketed for
the analyte, CUZD1, recognized a different non-
homologous antigen, CA125. The authors indicated that
many commercial manufacturers acquire their reagent
Fig. 1 Post-operative serum SIRPA concentration from 54 patients
using Cusabio SIRPA ELISA kit. Patients were grouped into no
ventriculotomy (n = 28), myectomy (n = 14), ventriculotomy (n = 7)
and non-cardiac surgery i.e. liver and renal transplants as negative
controls (n = 6). Post-operative serum SIRPA concentrations were
significantly higher in patients receiving ventriculotomy compared
to other groups (*p < 0.0001 vs no ventriculotomy, §p = 0.0004 vs
myectomy and †p = 0.0001 vs non-cardiac)
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from external suppliers without rigorous quality assur-
ance. In another study, an ELISA assay from USCN Life
Sciences, designed to analyze soluble hemojuvelin in
humans was unable to quantify human hemojuvelin but
detected a different unknown antigen [13].
To explore the validity of SIRPA as a biomarker of car-
diac injury will require development of a sensitive mass
spectrometry based targeted method for serum samples
as no other validated assay is currently available. Also,
we did not perform experiments to determine limits of
detection of SIRPA in human serum since this was be-
yond the scope of our current study.
Conclusion
The growing interest in biomarker discovery research
for new diagnostic and therapeutic targets has seen the
market flooded with antibodies and ELISA kits from
vendors that are marketed “for Research purposes only”.
These commercially available assays offer an attractive
option to rapidly screen for candidate proteins in large
sample sets due to ease of availability, ease of operation,
ability to test multiple samples and/or multiplex assays.
However, our report and other reports suggest that cau-
tion should be exercised when using commercial re-
search grade ELISA kits because they may be
incompletely characterized and validated, and results
from these assays should be interpreted with extreme
caution until systematic and independent validation is
performed to verify the findings [14, 15]. This is critical
in order to avoid the risk of false biomarker discovery
and chasing spurious targets.
Additional file
Additional file 1: Table S1. Mass spectrometry analysis of rhSIRPA
protein. Table S2. Mass spectrometry analysis of calibrator from SIRPA
ELISA kit (Cusabio). Table S3. Mass spectrometry analysis of calibrator
from Elabscience SIRPA ELISA kit. (DOCX 37 kb)
Fig. 2 Cusabio and Elabscience SIRPA ELISA kits failed to recognize recombinant human SIRPA protein. a Cusabio SIRPA ELISA kit (CSB-EL021334HU)
recognized its own calibrator diluted in buffer from Cusabio ELISA kit generating a linear curve (diamonds) but did not recognize recombinant human
SIRPA protein (squares); b Elabscience SIRPA ELISA kit (E-EL-H1573) recognized its own calibrator diluted in buffer from Elabscience ELISA kit generating
a linear curve (diamonds) but did not recognize recombinant human SIRPA protein (squares). X- axis represents known standard concentration (ng/ml)
and Y-axis represents optical density (OD) measured at 450 nm. c Western blot of rhSIRPA using SIRPA antibody (Biolegend, catalog # 323805) detected
a ~55 kda band in rhSIRPA but not in calibrators from Cusabio and Elabscience SIRPA ELISA kits
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